Brivudine

Jump to: navigation, search
Brivudine
Brivudine.png
Clinical data
AHFS/Drugs.comInternational Drug Names
Pregnancy
category
  • exclusion
Routes of
administration
oral
ATC code
Pharmacokinetic data
Bioavailability30%
Elimination half-life16 hours
Excretionmainly renal
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC11H13BrN2O5
Molar mass333.135 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Brivudine

Articles

Most recent articles on Brivudine

Most cited articles on Brivudine

Review articles on Brivudine

Articles on Brivudine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Brivudine

Images of Brivudine

Photos of Brivudine

Podcasts & MP3s on Brivudine

Videos on Brivudine

Evidence Based Medicine

Cochrane Collaboration on Brivudine

Bandolier on Brivudine

TRIP on Brivudine

Clinical Trials

Ongoing Trials on Brivudine at Clinical Trials.gov

Trial results on Brivudine

Clinical Trials on Brivudine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Brivudine

NICE Guidance on Brivudine

NHS PRODIGY Guidance

FDA on Brivudine

CDC on Brivudine

Books

Books on Brivudine

News

Brivudine in the news

Be alerted to news on Brivudine

News trends on Brivudine

Commentary

Blogs on Brivudine

Definitions

Definitions of Brivudine

Patient Resources / Community

Patient resources on Brivudine

Discussion groups on Brivudine

Patient Handouts on Brivudine

Directions to Hospitals Treating Brivudine

Risk calculators and risk factors for Brivudine

Healthcare Provider Resources

Symptoms of Brivudine

Causes & Risk Factors for Brivudine

Diagnostic studies for Brivudine

Treatment of Brivudine

Continuing Medical Education (CME)

CME Programs on Brivudine

International

Brivudine en Espanol

Brivudine en Francais

Business

Brivudine in the Marketplace

Patents on Brivudine

Experimental / Informatics

List of terms related to Brivudine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Brivudine is an antiviral drug used in the treatment of herpes zoster.

History

Brivudine is a similar drug to acyclovir[clarification needed]. The compound was first synthesized by scientists at the University of Birmingham in the UK in the 1970s. It was shown to be a potent inhibitor of the herpes simplex virus Type 1 (HSV-1) as well as the varicella zoster virus (VZV) by Erik De Clercq at the Rega Institute for Medical Research in Belgium in 1979. In the 1980s the drug became commercially available in East Germany, where it was marketed as Helpin by a pharmaceutical company called Berlin-Chemie.

Approvals

Brivudine is approved for use in Germany and other European countries including Italy.

Mechanism of Action

Brivudine is an analogue of the nucleoside thymidine. The drug works because it is able to be incorporated into the viral DNA, but then blocks the action of DNA polymerases, thus inhibiting viral replication. The active compound is the 5'-triphosphate of BVDU, which is formed in subsequent phosphorylations by viral thymidine kinase and presumably by nucleoside diphosphate kinase.

Research

A Cochrane Systematic Review examined the effectiveness of multiple antiviral drugs in the treatment of herpes simplex virus epithelial keratitis. Brivudine was found to be significantly more effective than idoxuridine in increasing the number of successfully healed eyes of participants.[1]

The drug's name

Brivudine derives from the drug's chemical name of bromovinyldeoxyuridine or BVDU for short. The drug's full chemical description is (E)-5-(2-bromovinyl)-2-deoxyuridine. It is also sold as Bridic, Brivox, Brivudin, Helpin, Zerpex, Zonavir and Zostex.

Suppliers

Brivudine main supplier is Berlin-Chemie, now part of Italy's Menarini Group. The drug is approved for sale in Austria, Belgium, Germany, Greece, Italy, Luxembourg, Portugal and Spain. In Central America is provided Menarini Centro America and Wyeth.

References

  1. Wilhelmus KR (2010). "Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis". Cochrane Database Syst Rev. 12: CD002898. doi:10.1002/14651858.CD002898.pub4. PMID 21154352.

Linked-in.jpg